Camrelizumab (SHR-1210) is a high-affinity, humanized IgG4-?? monoclonal antibody that targets the PD-1 receptor. This antibody demonstrates a binding affinity of 3 nM for PD-1 and effectively inhibits the PD-1/PD-L1 interaction with an IC50 of 0.70 nM. As an anti-PD-1/PD-L1 therapeutic agent, Camrelizumab is utilized in the investigation of various cancers, including non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), Hodgkin lymphoma, and advanced hepatocellular carcinoma (HCC), among others. This specificity and potency make it a valuable tool in oncology research, facilitating the exploration of immune checkpoint pathways and their role in immune evasion by tumors.
Camrelizumab (SHR-1210) is a high-affinity, humanized IgG4-?? monoclonal antibody that targets the PD-1 receptor. This antibody demonstrates a binding affinity of 3 nM for PD-1 and effectively inhibits the PD-1/PD-L1 interaction with an IC50 of 0.70 nM. As an anti-PD-1/PD-L1 therapeutic agent, Camrelizumab is utilized in the investigation of various cancers, including non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), Hodgkin lymphoma, and advanced hepatocellular carcinoma (HCC), among others. This specificity and potency make it a valuable tool in oncology research, facilitating the exploration of immune checkpoint pathways and their role in immune evasion by tumors.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
